Following Veeva’s (VEEV) quarterly release of it latest Pulse Field Trends report shedding light on trends in healthcare provider engagement, Raymond James noted that while email volume as a mode of engagement with HCPs has grown significantly, open rates were seen ticking 2% lower globally and more precipitously down 5% in the U.S. This suggests that life sciences organizations will need to continue to invest in novel sales and marketing channels, as well as prioritize campaign attribution and analytics, to ensure efficient and effective provider access, which has positive reads for Doximity (DOCS) and Veeva, respectively, the analyst tells investors. The firm has Outperform ratings on both stocks.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $60 from $63 at JPMorgan
- Doximity call volume above normal and directionally bullish
- Doximity price target lowered to $50 from $80 at Goldman Sachs
- Doximity price target lowered to $65 from $87 at Baird
- Doximity’s Stock Decline Offers a Compelling Buy Opportunity Amid Strong Performance and Growth Potential
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue